Share This Author
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
It is found that among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without and a greater number ofComorbidities also correlated with poorer clinical outcome.
Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China
There were more severe cases and poorer outcomes for COVID-19 patients treated in Hubei, which might be attributed to the prolonged duration of symptom onset to hospitalisation in the epicentre, and the reason for delaying hospitalisation is warranted.
Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey
The findings suggest that there is considerable room for improvement in the management of COPD, and highlight a need to enhance patient and physician education in the region.
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study
Association between Air Pollutants and Asthma Emergency Room Visits and Hospital Admissions in Time Series Studies: A Systematic Review and Meta-Analysis
Short-term exposures to air pollutants account for increased risks of asthma-related ERVs and hospitalizations that constitute a considerable healthcare utilization and socioeconomic burden.
Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China
Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis
Comorbidities are present in around one fourth of patients with COVID-19 in China, and predispose to poorer clinical outcomes, and have significantly escalated risks of reaching to the composite endpoint compared with those who had a single comorbidity.
Tiotropium in Early‐Stage Chronic Obstructive Pulmonary Disease
Tiotropium resulted in a higher FEV1 than placebo at 24 months and ameliorated the annual decline in theFEV1 after bronchodilator use in patients with COPD of GOLD stage 1 or 2.
Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease.
- Jing Li, Jinping Zheng, Jin-ping Yuan, G. Zeng, N. Zhong, Cai Lin
- MedicineChinese medical journal
- 1 June 2004
Orally administered Broncho-Vaxom is associated with a decreases in the incidence of acute exacerbation and a decrease in the need for antibiotics and symptomatic relief medications in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease.